-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YPP-10 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YPP-10 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YPP-10 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: YP-P10...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-2074 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-2074 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-2074 in Gastric Cancer Drug Details: ASP-2074 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutikizumab in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutikizumab in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutikizumab in Hidradenitis Suppurativa Drug Details: Lutikizumab is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Epithelial Ovarian Cancer Drug Details: Camrelizumab (Airuika) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST-316 in Metastatic Adenocarcinoma of The Pancreas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ST-316 in Metastatic Adenocarcinoma of The PancreasDrug Details:ST-316 is under development for the treatment of breast...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efinopegdutide in Non Alcoholic Fatty Liver Disease (NAFLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efinopegdutide in Non Alcoholic Fatty Liver Disease (NAFLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Efinopegdutide in Non Alcoholic Fatty Liver Disease (NAFLD)Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Fibrosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Fibrosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Fibrosarcoma Drug Details: Toripalimab (Tuoyi) is a monoclonal antibody, acts as...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – YPP-10
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry YPP-10 Drug Details YP-P10 is under development for the treatment of keratoconjunctivitis sicca (dry...